

P1485

Abstract (poster session)

In vitro activity of tigecycline against commonly-isolated pathogens of skin and skin structure infections in Europe: TEST 2009-2010

S. Bouchillon*, M. Hackel, D. Hoban, R. Badal, S. Hawser, M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)

Background: Tigecycline has been approved for the treatment of complicated skin and skin structure infections (SSTIs) in Europe since 2006. Since introduction, tigecycline has shown little development of resistance to common pathogens of SSTIs. The Tigecycline European Surveillance Trial (TEST) has been monitoring susceptibility of tigecycline since 2004. This study reports on the activity of tigecycline against recent clinical isolates from SSTIs in Europe. Methods: A total of 6,880 clinical isolates from SSTI were collected and identified in 25 countries in Europe in 2009-2010. MICs were determined by broth microdilution (aerobes) or agar dilution (anaerobes) using CLSI guidelines. Susceptibility of tigecycline was interpreted using EUCAST and FDA (anaerobes) breakpoints as available. Results: Results of tigecycline activity are summarized below: na - breakpoints not defined. FDA breakpoints used for anaerobes. Conclusions: Tigecycline demonstrated potent in vitro activity against the vast majority of recent isolates from SSTI including gram-negative, gram-positive, aerobe and anaerobe pathogens. MIC90 values ranged from ≤ 0.06 to 2 mcg/ml. Three species, *Enterobacter*, *K. pneumoniae*, and *Serratia*, had % susceptibility $<90\%$ using EUCAST breakpoints.

Organism	n	MIC ₅₀	MIC ₉₀	%S
<i>Acinetobacter</i> spp.	586	0.5	2	na
<i>Bacteroides</i> spp.	519	0.5	2	98
<i>Clostridium</i> spp.	149	≤ 0.06	0.5	99
<i>Enterobacter</i> spp.	914	0.5	2	88
<i>Enterococcus faecalis</i>	435	0.12	0.25	100
<i>Enterococcus faecium</i>	145	0.06	0.25	99
<i>Escherichia coli</i>	823	0.25	0.5	99
<i>Finnegoldia magna</i>	134	≤ 0.06	0.25	100
<i>Klebsiella pneumoniae</i>	492	0.5	2	86
<i>Peptoniphilus</i> spp.	46	≤ 0.06	0.06	100
<i>Peptostreptococcus</i> spp	238	≤ 0.06	0.12	100
<i>Prevotella</i> spp.	243	0.12	0.5	100
<i>Serratia</i> spp.	368	1	2	67
<i>Staphylococcus aureus</i>	1457	0.12	0.25	100
MRSA	282	0.25	0.5	100
MSSA	1175	0.12	0.25	100
<i>Streptococcus agalactiae</i>	331	0.06	0.12	100